Bac D J, Kok T C, van der Gaast A, Splinter T A
Department of Medical Oncology, University Hospital Dijkzigt, Rotterdam, The Netherlands.
J Cancer Res Clin Oncol. 1991;117(3):263-5. doi: 10.1007/BF01625436.
Between 1987 and 1990 21 patients with proven adenocarcinoma of the pancreas were treated with chemotherapy in four different phase II studies. For 14 patients, serial measurements of CA19-9 serum levels and clinical evaluations of response by computed tomography scan and/or ultrasound were available. Clinical stable disease and progressive disease were accompanied by stable or exponentially rising serum levels of CA19-9. One patient with clinical partial remission showed a 90% decline of CA19-9. However, a 75% decline of CA19-9 was also observed in a patient with rapidly progressive disease. These data seem to indicate that the CA19-9 serum level may be used as an easy and sensitive tool to evaluate progressive disease during chemotherapy.
1987年至1990年间，21例经证实的胰腺腺癌患者在四项不同的II期研究中接受了化疗。对于14例患者，可获得CA19-9血清水平的系列测量值以及通过计算机断层扫描和/或超声进行的反应临床评估。临床稳定疾病和疾病进展伴随着CA19-9血清水平稳定或呈指数上升。一名临床部分缓解的患者CA19-9下降了90%。然而，一名疾病快速进展的患者CA19-9也下降了75%。这些数据似乎表明，CA19-9血清水平可作为评估化疗期间疾病进展的一种简便且敏感的工具。
